These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 12243811)

  • 1. Prognostic value of TP53 transcriptional activity on p21 and bax in patients with esophageal squamous cell carcinomas treated by definitive chemoradiotherapy.
    Michel P; Magois K; Robert V; Chiron A; Lepessot F; Bodenant C; Roque I; Seng SK; Frebourg T; Paillot B
    Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):379-85. PubMed ID: 12243811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bax expression as a prognostic marker of postoperative chemoradiotherapy for patients with esophageal cancer.
    Ikeguchi M; Maeta M; Kaibara N
    Int J Mol Med; 2001 Apr; 7(4):413-7. PubMed ID: 11254884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The biomarker TP53 divides patients with neoadjuvantly treated esophageal cancer into 2 subgroups with markedly different outcomes. A p53 Research Group study.
    Kandioler D; Schoppmann SF; Zwrtek R; Kappel S; Wolf B; Mittlböck M; Kührer I; Hejna M; Pluschnig U; Ba-Ssalamah A; Wrba F; Zacherl J
    J Thorac Cardiovasc Surg; 2014 Nov; 148(5):2280-6. PubMed ID: 25135238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of response to chemo-radiotherapy and radiotherapy for esophageal squamous cell carcinoma.
    Miyazaki T; Kato H; Faried A; Sohda M; Nakajima M; Fukai Y; Masuda N; Manda R; Fukuchi M; Ojima H; Tsukada K; Kuwano H
    Anticancer Res; 2005; 25(4):2749-55. PubMed ID: 16080521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant concurrent chemoradiotherapy followed by definitive high-dose radiotherapy or surgery for operable thoracic esophageal carcinoma.
    Murakami M; Kuroda Y; Okamoto Y; Kono K; Yoden E; Kusumi F; Hajiro K; Matsusue S; Takeda H
    Int J Radiat Oncol Biol Phys; 1998 Mar; 40(5):1049-59. PubMed ID: 9539559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 Mutation status predicts pathological response to chemoradiotherapy in locally advanced esophageal cancer.
    Makino T; Yamasaki M; Miyata H; Yoshioka S; Takiguchi S; Fujiwara Y; Nakajima K; Nishida T; Mori M; Doki Y
    Ann Surg Oncol; 2010 Mar; 17(3):804-11. PubMed ID: 19885698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value of p53 and 14-3-3sigma for the effect of chemoradiation therapy on esophageal squamous cell carcinoma.
    Okumura H; Natsugoe S; Matsumoto M; Yokomakura N; Uchikado Y; Takatori H; Ishigami S; Takao S; Aikou T
    J Surg Oncol; 2005 Jul; 91(1):84-9. PubMed ID: 15999354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VEGF -634C/G genotype is predictive of long-term survival after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.
    Tamura T; Kuwahara A; Yamamori M; Nishiguchi K; Nakamura T; Okuno T; Miki I; Manabe Y; Sakaeda T
    Int J Med Sci; 2012; 9(10):833-7. PubMed ID: 23155356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PRIMA-1 induces p53-mediated apoptosis by upregulating Noxa in esophageal squamous cell carcinoma with TP53 missense mutation.
    Furukawa H; Makino T; Yamasaki M; Tanaka K; Miyazaki Y; Takahashi T; Kurokawa Y; Nakajima K; Takiguchi S; Mori M; Doki Y
    Cancer Sci; 2018 Feb; 109(2):412-421. PubMed ID: 29168598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive factors of survival in patients treated with definitive chemoradiotherapy for squamous cell esophageal carcinoma.
    Di Fiore F; Lecleire S; Rigal O; Galais MP; Ben Soussan E; David I; Paillot B; Jacob JH; Michel P
    World J Gastroenterol; 2006 Jul; 12(26):4185-90. PubMed ID: 16830371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 genotype predicts response to chemotherapy in patients with squamous cell carcinoma of the esophagus.
    Yamasaki M; Miyata H; Fujiwara Y; Takiguchi S; Nakajima K; Nishida T; Yasuda T; Matsuyama J; Mori M; Doki Y
    Ann Surg Oncol; 2010 Feb; 17(2):634-42. PubMed ID: 19941080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma.
    Perrone F; Bossi P; Cortelazzi B; Locati L; Quattrone P; Pierotti MA; Pilotti S; Licitra L
    J Clin Oncol; 2010 Feb; 28(5):761-6. PubMed ID: 20048189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors after chemoradiotherapy for patients with inoperable esophageal squamous cell carcinoma.
    Kunisaki C; Imada T; Yamada R; Hatori S; Kinbara K; Watai K; Akiyama H; Nomura M; Matsuda G; Otsuka Y; Ono H; Shimada H
    Hepatogastroenterology; 2006; 53(69):366-71. PubMed ID: 16795974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of concurrent chemoradiotherapy on serum vascular endothelial growth factor in esophageal squamous cell carcinoma patients--a report of 43 cases].
    Wang XS; Liu MZ; Zhang CQ; Cai L; Cui NJ
    Ai Zheng; 2006 Nov; 25(11):1428-32. PubMed ID: 17094915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High expression of EZH2 is associated with tumor aggressiveness and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy.
    He LR; Liu MZ; Li BK; Jia WH; Zhang Y; Liao YJ; Chen YC; Zhang LJ; Guan XY; Zeng YX; Kung HF; Xie D
    Int J Cancer; 2010 Jul; 127(1):138-47. PubMed ID: 19904743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Phase II clinical trial of concurrent chemoradiotherapy (cisplatin plus 5-fluorouracil) for esophageal cancer].
    Lin Q; Gao XS; Qiao XY; Chen K; Wang YD; Zhou ZG
    Ai Zheng; 2008 Oct; 27(10):1077-81. PubMed ID: 18851788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endoscopic response predicts for survival and organ preservation after primary chemoradiotherapy for esophageal cancer.
    Lim JT; Truong PT; Berthelet E; Pai H; Joe H; Wai E; Larsson S; Kader HA; Weinerman B; Wilson K; Olivotto IA
    Int J Radiat Oncol Biol Phys; 2003 Dec; 57(5):1328-35. PubMed ID: 14630270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The telomere/telomerase binding factor PinX1 is a new target to improve the radiotherapy effect of oesophageal squamous cell carcinomas.
    Qian D; Zhang B; He LR; Cai MY; Mai SJ; Liao YJ; Liu YH; Lin MC; Bian XW; Zeng YX; Huang JJ; Kung HF; Xie D
    J Pathol; 2013 Apr; 229(5):765-74. PubMed ID: 23341363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors in esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiation therapy.
    Okumura H; Uchikado Y; Matsumoto M; Owaki T; Kita Y; Omoto I; Sasaki K; Sakurai T; Setoyama T; Nabeki B; Matsushita D; Ishigami S; Hiraki Y; Nakajo M; Natsugoe S
    Int J Clin Oncol; 2013 Apr; 18(2):329-34. PubMed ID: 22350023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of AIB1 predicts resistance to chemoradiotherapy and poor prognosis in patients with primary esophageal squamous cell carcinoma.
    He LR; Liu MZ; Li BK; Rao HL; Deng HX; Guan XY; Zeng YX; Xie D
    Cancer Sci; 2009 Sep; 100(9):1591-6. PubMed ID: 19552757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.